tradingkey.logo
tradingkey.logo
Search

Jupiter Neurosciences Inc

JUNS
Add to Watchlist
0.093USD
-0.005-4.82%
Close 07-31 16:00ETQuotes delayed by 15 min
3.37MMarket Cap
LossP/E TTM

Jupiter Neurosciences Inc

0.093
-0.005-4.82%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-4.82%

5 Days

-23.31%

1 Month

-56.68%

6 Months

-82.42%

Year to Date

-90.90%

1 Year

-93.37%

Key Figures
0.089Open
0.096High
23.06MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
63.55%Turnover Ratio
0.098Prev. Close
0.083Low
1.46MTurnover
LossP/E Static
-1.21P/B
0.00%Div Yield TTM
-205.98%ROA
3.33052wk High
7.47Volume Ratio
-2.44MNet Profit
36.28MShares
-0.2620EPS TTM
--Beta
-6529.17%ROE
0.17252wk Low
12.82%Amplitude
76.61%Gross Margin
3.37MMarket Cap
-7.50Reward/Risk
7.51%Risk Rate

Key Insights

Jupiter Neurosciences Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 200 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Jupiter Neurosciences Inc's Score

Industry at a Glance

Industry Ranking
200 / 385
Overall Ranking
371 / 4281
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

Jupiter Neurosciences Inc Highlights

StrengthsRisks
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Growing
The company is in a growing phase, with the latest annual income totaling USD 21.80K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 21.80K.
Overvalued
The company’s latest PE is -0.34, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.06M shares, increasing 42.85% quarter-over-quarter.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
25.000
Target Price
0.00%
Upside Space

Jupiter Neurosciences Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 1 analysts
Buy
Current Rating
25.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Jupiter Neurosciences Inc
JUNS
1
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(4)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.011
Sell
RSI(14)
20.675
Sell
STOCH(KDJ)(9,3,3)
4.161
Oversold
ATR(14)
0.026
High Vlolatility
CCI(14)
-112.232
Sell
Williams %R
95.691
Oversold
TRIX(12,20)
-2.448
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
0.102
Sell
MA10
0.129
Sell
MA20
0.160
Sell
MA50
0.208
Sell
MA100
0.293
Sell
MA200
0.657
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Jupiter Neurosciences Inc Info

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Ticker SymbolJUNS
CompanyJupiter Neurosciences Inc
CEORosen (Christer)
Websitehttps://jupiterneurosciences.com/

Shareholders

Shareholders
Shareholders
Proportion
Rosen (Christer)
30.53%
Hayward (Marshall A Ph.D.)
8.26%
Wahlestedt (Claes M.D., Ph.D.)
7.80%
Brothers (Shaun P.)
4.45%
Vestor Capital Partners, LLC
2.68%
Other
46.29%

FAQs

What is the current price of Jupiter Neurosciences Inc (JUNS)?

The current price of Jupiter Neurosciences Inc (JUNS) is 0.09.

What is the symbol of Jupiter Neurosciences Inc?

The ticker symbol of Jupiter Neurosciences Inc is JUNS.

What is the 52-week high of Jupiter Neurosciences Inc?

The 52-week high of Jupiter Neurosciences Inc is 3.33.

What is the 52-week low of Jupiter Neurosciences Inc?

The 52-week low of Jupiter Neurosciences Inc is 0.17.

What is the market capitalization of Jupiter Neurosciences Inc?

The market capitalization of Jupiter Neurosciences Inc is 3.37M.

Is Jupiter Neurosciences Inc (JUNS) currently rated as Buy, Hold, or Sell?

According to analysts, Jupiter Neurosciences Inc (JUNS) has an overall rating of Buy, with a price target of 25.00.

What is the Earnings Per Share (EPS TTM) of Jupiter Neurosciences Inc (JUNS)?

The Earnings Per Share (EPS TTM) of Jupiter Neurosciences Inc (JUNS) is -0.25.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.